查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1929601

親水性冠狀動脈支架市場（按支架類型、藥物類型、聚合物材料、支架尺寸、臨床用途和最終用戶分類），全球預測，2026-2032年

Hydrophilic Coronary Stents Market by Stent Type, Drug Type, Polymer Material, Stent Size, Clinical Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年親水性冠狀動脈支架市值為13.2億美元，預計2026年將成長至14.2億美元，預計到2032年將達到20.9億美元，複合年成長率為6.81%。

關鍵市場統計數據
基準年 2025 13.2億美元
預計年份：2026年 14.2億美元
預測年份 2032 20.9億美元
複合年成長率 (%) 6.81%

本文簡要概述了親水性冠狀動脈支架的發展歷程，重點介紹了臨床創新、監管壓力和手術應用趨勢。

親水性冠狀動脈支架已從一項小眾創新發展成為現代介入性心臟病學中不可或缺的工具。透過將表面工程與臨床應用相結合，它們能夠減少急性手術併發症並促進血管癒合。塗層化學、聚合物選擇和抗增殖藥物整合的進步顯著提升了支架的性能，而手術和影像輔助技術的進步也最佳化了支架的配置和長期通暢率。因此，臨床醫師和採購團隊會從即時輸送性、生物相容性和後續臨床療效等綜合觀點來評估支架的選擇。

技術創新、採購改革和臨床偏好的整合將如何重塑競爭格局和設備差異化

親水性冠狀動脈支架領域的變革是由技術、臨床和政策趨勢的整合所驅動的，這些趨勢共同重新定義了製造商和醫療服務提供者的價值創造。在技​​術方面，親水性塗層和先進聚合物基質的結合有望提高支架的輸送性能並減少內皮損傷。這激發了臨床對兼具易用性和良好癒合特性的器械的興趣。在臨床實踐中，器械的選擇越來越依賴於能夠證明器械特性與特定患者群體和病變亞型之間關聯性的證據，從而推動了從「一刀切」式選擇向精準器械匹配的轉變。

評估2025年美國關稅對供應鏈、籌資策略、合約架構和醫療服務提供者採購行為的影響

美國在2025年實施的關稅政策給親水性冠狀動脈支架生態系統帶來了巨大壓力，對製造商、供應商和醫療服務機構的成本、物流和策略都產生了影響。關稅提高了進口零件和成品的本地到貨成本，迫使製造商重新評估籌資策略、重新談判供應商契約，並在可能的情況下評估本地生產的替代方案。因此，一些供應商加快了近岸外包的步伐，以降低跨境課稅及其帶來的前置作業時間波動風險。

全面的細分洞察將支架採用模式與支架類型、藥物特性、臨床環境、聚合物選擇、尺寸和臨床環境聯繫起來

細分市場分析揭示了臨床選擇和採購偏好的細微促進因素。首先，按支架類型，我們分析了裸金屬支架和藥物釋放型支架（DGS）市場，重點闡述了每種支架類型如何對血管再阻塞風險、雙聯抗血小板治療持續時間和手術選擇產生不同的影響。同時，按藥物類型區分，重點在於依Everolimus、紫杉醇、Sirolimus和佐他莫司，著重闡述了每種抗增殖藥物如何影響內皮反應譜，並針對具有不同合併症和病變特徵的患者亞群調整其適用性。這些藥理學差異對臨床決策和製造商的研發藍圖至關重要。

全球各地的區域法規環境、採購結構和醫療保健基礎設施如何推動不同的採用路徑

區域趨勢正在影響親水性冠狀動脈支架的獲取途徑以及創新技術在臨床實踐中的應用路徑。在美洲，先進的手術基礎設施、整合的採購集團和完善的報銷機制使得三級醫療中心能夠快速採用創新器械，而農村和社區醫療機構則面臨運營方面的限制，影響其採購決策。該地區不同支付方構成和醫院所有權的差異，導致高容量心臟中心和資源匱乏的醫療機構之間的器械採用率存在差異。

分析競爭策略和策略聯盟，重點在於技術差異化、證據產生和供應鏈韌性

業內相關人員在產品開發、臨床證據產生和商業性夥伴關係採取了各具特色的方法。一些公司強調專有塗層技術或聚合物工程，以區分藥物遞送特性或癒合效果。另一些機構則專注於廣泛的臨床項目，收集不同病變亞型和臨床環境下的真實世界數據，從而建立能夠吸引介入性心臟病專家和醫院採購委員會的臨床案例。策略聯盟和經銷夥伴對於拓展地域覆蓋範圍仍然至關重要，尤其是在當地監管和報銷政策調整需要本地專業知識的地區。

為產業領導者提供切實可行的策略行動，以協調產品創新、供應鏈永續性和實證實踐與醫療服務提供者的優先事項。

為了應對不斷變化的臨床、監管和供應鏈壓力，產業領導者應優先採取一系列果斷行動，使產品開發與醫療服務提供者的需求和採購實踐保持一致。首先，投資強而有力的臨床證據項目，針對細分框架中所確定的不同亞群和手術場景。在非ST段抬高型心肌梗塞（NSTEMI）、ST段抬高型心肌梗塞（STEMI）和擇期手術中展現一致的性能，將顯著影響介入性心臟病專家的器械選擇。其次，透過供應商多元化、在可行的情況下採用近岸外包以及與高容量設施建立策略庫存合作夥伴關係，提高供應鏈的韌性，從而降低關稅和物流波動帶來的風險。

一項採用混合方法的研究，結合了臨床醫生訪談、採購分析和臨床檢驗三角驗證，旨在得出可操作的醫療器材見解。

本分析所依據的研究採用了混合方法，結合了有針對性的初步研究和全面的二手資料，以確保獲得平衡且具有臨床意義的觀點。初步研究包括與介入性心臟病專家、醫院和門診採購主管以及行業高管進行結構化訪談和討論，以收集有關器械選擇標準、供應鏈經驗和臨床偏好的第一手資訊。這些定性資料輔以手術流程和醫院採購模式的深入案例分析，使研究結果與實際操作相結合。

一份權威的綜合報告，重點闡述了臨床證據、供應彈性以及客製化商業策略在實現持續推廣應用方面的相互作用。

總之，親水性冠狀動脈支架處於材料科學、藥理學和介入技術的動態交會點，其應用受到細微的臨床需求、採購實際情況和不斷變化的監管預期的影響。塗層化學和聚合物選擇的進步正在顯著影響支架的輸送性和癒合效果，而藥物釋放型配方則持續影響支架在特定病變類型和患者群體中的適用性。隨著醫療機構越來越重視手術效率和整體手術價值，製造商必須將臨床差異化與供應的可預測性和支持服務相結合，以確保支架的持續應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 親水性冠狀動脈支架市場（依支架類型分類）

  • 裸金屬支架
  • 藥物釋放型支架

9. 依藥物類型分類的親水性冠狀動脈支架市場

  • Everolimus
  • 紫杉醇
  • Sirolimus
  • 佐他羅莫司

10. 依聚合物材料分類的親水性冠狀動脈支架市場

  • 可生物分解聚合物
  • 耐用聚合物

11. 依支架尺寸分類的親水性冠狀動脈支架市場

  • 18至28毫米
  • 超過 28 毫米
  • 小於18毫米

12. 親水性冠狀動脈支架市場（依臨床應用分類）

  • 急性冠狀動脈症候群
    • 非ST段上升型心肌梗塞（NSTEMI）
    • STEMI
    • 不穩定型心絞痛
  • 穩定性心絞痛

第13章 親水性冠狀動脈支架市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
    • 私立醫院
    • 公立醫院

第14章 親水性冠狀動脈支架市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 親水性冠狀動脈支架市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國親水性冠狀動脈支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國親水性冠狀動脈支架市場

第18章：中國親水性冠狀動脈支架市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Apollo Endosurgery, Inc.
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Endologix LLC
  • Hansen Medical, Inc.
  • Invuity, Inc.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Livar Stent Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Philips Healthcare
  • Relievant Medsystems, Inc.
  • Shanghai MicroPort Medical（Group）Co., Ltd.
  • Shanghai Shape Memory Alloy Co., Ltd.
  • Siemens Healthineers AG
  • Stryker Corporation
  • Terumo Corporation
  • Translumina GmbH & Co. KG
Product Code: MRR-0A3806951844

The Hydrophilic Coronary Stents Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.42 billion in 2026, with a CAGR of 6.81%, reaching USD 2.09 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.42 billion
Forecast Year [2032] USD 2.09 billion
CAGR (%) 6.81%

A concise framing of hydrophilic coronary stent evolution highlighting clinical innovation, regulatory pressure, and procedural adoption dynamics

Hydrophilic coronary stents have matured from niche innovations into essential tools within contemporary interventional cardiology, combining surface engineering with clinical intent to reduce acute procedural complications and improve vascular healing. Advances in coating chemistry, polymer choices, and antiproliferative drug integration have shifted device performance profiles, while procedural techniques and imaging adjuncts have evolved to optimize deployment and long-term patency. As a result, clinicians and procurement teams assess stent selection through an integrated lens of immediate deliverability, biocompatibility, and downstream clinical outcomes.

Concurrently, regulatory scrutiny and payer expectations are shaping product lifecycles, demanding robust clinical evidence and demonstrable value across heterogeneous care settings. Hospitals and ambulatory surgery centers have refined their device evaluation pathways to account for device handling, inventory turnover, and the relative ease of transition between stent platforms during complex procedures. This increased emphasis on total procedural value has pressured developers to prioritize both clinical differentiation and supply consistency.

Moreover, incremental innovations in drug formulations and polymer technologies continue to influence clinician preference and patient outcomes. These iterative improvements are prompting device-makers to consider not only efficacy but also logistical factors such as sterilization compatibility, shelf life, and cross-compatibility with delivery systems. Together, these forces create a dynamic environment in which hydrophilic coronary stents must demonstrate clear operational and clinical benefits to gain traction across diverse healthcare infrastructures.

How converging technological advances, procurement reforms, and clinical preferences are reshaping competitive dynamics and device differentiation

Transformation within the hydrophilic coronary stent landscape is being driven by convergent technological, clinical, and policy trends that collectively redefine value creation for manufacturers and care providers. Technologically, the integration of hydrophilic coatings with advanced polymer matrices has improved deliverability and may reduce endothelial trauma, thereby shifting clinical conversations toward devices that combine ease of use with favorable healing profiles. In clinical practice, adoption is increasingly shaped by evidence linking device characteristics to specific patient cohorts and lesion subsets, prompting a move away from one-size-fits-all selection toward precision device matching.

Policy and procurement mechanisms are also in flux. Value-based purchasing programs and hospital group purchasing negotiations emphasize demonstrable outcomes and total cost of ownership, incentivizing collaborations between device innovators and provider networks. Supply-chain resilience has emerged as a strategic priority, with manufacturers diversifying sourcing and manufacturing footprints to mitigate disruptions and ensure predictable supply. As a result, partnerships that bundle clinical training, device analytics, and post-market surveillance are gaining favor, because they address both clinical adoption barriers and institutional risk management.

Finally, the competitive landscape has prompted a wave of product differentiation that centers on drug-eluting profiles, polymer biodegradability, and stent geometries optimized for complex anatomies. These shifts have strengthened the role of targeted clinical evidence and real-world performance data in procurement decisions, leading to iterative cycles of device refinement and focused market entry strategies that respond directly to clinician feedback and hospital procurement criteria.

Assessment of the 2025 United States tariff effects on supply chains, sourcing strategies, contractual frameworks, and provider purchasing behavior

The imposition of United States tariffs in 2025 has introduced notable pressures across the hydrophilic coronary stent ecosystem, imposing cost, logistical, and strategic implications for manufacturers, suppliers, and provider organizations. Tariffs have elevated the landed cost of imported components and finished devices, prompting manufacturers to reassess sourcing strategies, renegotiate supplier contracts, and evaluate local manufacturing alternatives where feasible. Consequently, some suppliers accelerated nearshoring initiatives to reduce exposure to cross-border levies and associated lead-time variability.

For manufacturers that rely on specialized raw materials or coating chemistries sourced internationally, tariffs have compressed margins or required selective repositioning of product portfolios to protect supplier relationships and maintain price competitiveness. In response, several producers have intensified supplier diversification efforts and sought alternative material formulations that either avoid tariffed categories or can be sourced from non-affected jurisdictions. These efforts were accompanied by operational investments to improve yield and reduce waste, thereby offsetting some tariff-driven cost increases.

Healthcare providers have experienced indirect effects through procurement negotiations and inventory management. Purchasing teams have pressed vendors for price relief, bundled service agreements, and longer-term supply commitments to stabilize device availability and control episodic cost pressures. In parallel, contracting strategies have emphasized multi-year agreements and contingency clauses that account for tariff variability, while clinical teams prioritized devices with proven deliverability to limit procedural complexity that could magnify cost impacts.

Regulatory and reimbursement environments have further amplified the tariff effect by tightening cost-containment expectations. Payers increasingly evaluated the comparative clinical benefits relative to total procedural expenditure, encouraging device suppliers to articulate clear value propositions. In summary, the 2025 tariffs accelerated supply-chain reconfiguration, encouraged sourcing agility, and reshaped contract frameworks across the industry, catalyzing strategic responses that prioritize resilience and demonstrable clinical value.

Comprehensive segmentation-driven insights connecting stent types, drug profiles, clinical contexts, polymer choices, sizing, and care settings to adoption patterns

Segmentation insights reveal nuanced drivers of clinical choice and procurement preference, beginning with stent type where the market is analyzed across Bare-Metal Stent and Drug-Eluting Stent and each category brings distinct implications for restenosis risk, dual antiplatelet therapy duration, and procedural selection. In parallel, drug-type differentiation focuses on Everolimus, Paclitaxel, Sirolimus, and Zotarolimus, with each antiproliferative agent influencing endothelial response profiles and tailoring suitability for patient subgroups with varying comorbidities and lesion characteristics. These pharmacologic distinctions are central to clinical decision-making and to manufacturers' development roadmaps.

Clinical application segmentation distinguishes Acute Coronary Syndrome and Stable Angina as primary therapeutic contexts, with the Acute Coronary Syndrome category further dissected into NSTEMI, STEMI, and Unstable Angina to reflect heterogeneous procedural urgency and lesion complexity. This granularity clarifies how device attributes such as deliverability, rapid deployment, and thrombogenicity bear differently on emergent versus elective interventions. Polymer material choices are another critical axis, compared across Biodegradable Polymer and Durable Polymer, since polymer behavior affects drug elution kinetics, inflammatory response, and medium-term vessel healing.

Stent size segmentation-18 To 28 Mm, Over 28 Mm, and Under 18 Mm-captures anatomical fit considerations and the engineering trade-offs between radial strength and flexibility. End-user segmentation contrasts Ambulatory Surgical Center and Hospital settings, with Hospital further divided into Private Hospital and Public Hospital, highlighting differences in purchasing cycles, procedural throughput, and capital constraints that influence product adoption. Taken together, these segmentation lenses offer a multidimensional framework for understanding clinical adoption patterns, procurement preferences, and the technical choices manufacturers must prioritize to address distinct user needs.

How regional regulatory environments, procurement structures, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics shape both access to hydrophilic coronary stents and the pathways through which innovations achieve clinical traction, beginning with the Americas where advanced procedural infrastructure, consolidated purchasing groups, and established reimbursement frameworks enable rapid incorporation of device innovations into tertiary centers, while rural and community settings present operational constraints that influence procurement decisions. In this region, variations in payer mix and hospital ownership models create differentiated adoption speeds between high-volume cardiology centers and resource-constrained facilities.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in some jurisdictions coexists with fragmented procurement practices in others, producing diverse entry strategies for device manufacturers. Public hospital procurement in several countries exerts downward price pressure, yet centers of clinical excellence and private hospitals often act as early adopters of advanced device platforms, especially where evidence demonstrates procedural or post-procedural efficiencies. Logistics and distribution networks in this combined region require flexible supply arrangements to accommodate cross-border regulatory nuances and varied reimbursement policies.

Asia-Pacific encompasses both highly developed health systems and rapidly expanding access in emerging economies, creating dual pathways for adoption. Leading tertiary hospitals in urban centers frequently participate in clinical evaluations and can catalyze regional diffusion, while expanding ambulatory surgical infrastructure and growing cardiology service lines in secondary cities create new points of care for device use. Across this region, local manufacturing partnerships, regulatory approvals tailored to national requirements, and cost-sensitive procurement are central determinants of how quickly new hydrophilic stent innovations become standard practice.

Profiling competitive approaches and strategic alignments that emphasize technological differentiation, evidence generation, and supply-chain resilience

Industry participants have adopted distinct approaches to product development, clinical evidence generation, and commercial partnerships, with some companies emphasizing proprietary coating technologies and polymer engineering to differentiate on deliverability and healing profiles. Other organizations focus efforts on broad clinical programs that generate real-world performance data across diverse lesion subsets and care settings, creating clinical narratives that resonate with interventional cardiologists and hospital purchasing committees. Strategic alliances and distribution partnerships remain critical to expanding geographic reach, particularly where local regulatory navigation and reimbursement alignment require on-the-ground expertise.

Competition has also centered on lifecycle management, where incremental device upgrades and platform extensions reduce barriers to clinician transition while preserving existing capital equipment compatibility. Several firms have invested in training and proctoring programs to accelerate adoption, recognizing that clinician familiarity with delivery systems materially influences procedural efficiency. Meanwhile, quality and manufacturing consistency have become non-negotiable as providers prioritize supply reliability amid global procurement pressures.

Finally, new entrants and established manufacturers alike are exploring vertical integration strategies spanning coating suppliers, delivery system manufacturers, and clinical-support services. By controlling more elements of the value chain, these organizations aim to deliver bundled solutions that simplify procurement, shorten onboarding timelines, and provide measurable improvements in procedural outcomes and operational predictability.

Pragmatic strategic actions for industry leaders to align product innovation, supply resilience, and evidence generation with provider priorities

To navigate evolving clinical, regulatory, and supply-chain pressures, industry leaders should prioritize a set of decisive actions that align product development with provider needs and procurement realities. First, invest in robust clinical evidence programs that target the distinct subpopulations and procedural contexts identified in the segmentation framework; demonstrating consistent performance across NSTEMI, STEMI, and elective interventions will materially influence device preference among interventional cardiologists. Second, accelerate supply-chain resilience through supplier diversification, nearshoring where practical, and strategic inventory partnerships with high-volume centers to mitigate tariff and logistics volatility.

Third, tailor commercial offers to the end-user profile by developing differentiated value propositions for Ambulatory Surgical Center adoption versus Hospital settings, with specific contractual terms that address throughput, training, and service commitments. Fourth, prioritize polymer and drug formulation innovation that balances long-term vessel healing with clinician-handling preferences, while investing in incremental device ergonomics to reduce procedural complexity. Fifth, enhance post-market surveillance capabilities and real-world data collection to substantiate claims around deliverability, healing, and complication rates, thereby strengthening reimbursement conversations and procurement negotiations.

Lastly, foster collaborative relationships with clinical leaders and payers to co-develop pathways that align device selection with patient outcomes and cost-efficiency goals. By integrating clinical training, demonstrable evidence, and resilient supply practices into commercial strategies, manufacturers and distributors can secure durable partnerships and ensure sustained adoption across heterogeneous care environments.

A mixed-methods research approach combining clinician interviews, procurement analysis, and clinical evidence triangulation to produce actionable device insights

The research underpinning this analysis employed a mixed-methods approach combining targeted primary research with comprehensive secondary source synthesis to ensure balanced, clinically informed perspectives. Primary research included structured interviews and discussions with interventional cardiologists, procurement leaders in hospital and ambulatory settings, and industry executives to capture firsthand insights on device selection criteria, supply-chain experiences, and clinical preferences. These qualitative inputs were supplemented by detailed case reviews of procedural workflows and hospital procurement models to contextualize findings within operational realities.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available clinical registries to validate mechanistic claims regarding stent coatings, polymer behaviors, and drug-elution profiles. To maintain analytical rigor, triangulation methods were applied, cross-referencing clinical evidence with practitioner insights and supply-chain observations to identify consistent patterns and reconcile divergent viewpoints. The methodology also included comparative analysis of regional regulatory pathways and procurement frameworks to ensure that recommendations reflect practical adoption constraints across geographies.

Data synthesis emphasized transparency regarding source provenance and the limitations inherent in any evidence base, particularly where long-term comparative outcome data are limited. Throughout the process, methodological choices prioritized reproducibility and relevance to decision-makers seeking actionable intelligence on product development, commercial strategy, and clinical adoption pathways.

A conclusive synthesis emphasizing the interplay of clinical evidence, supply resilience, and tailored commercial strategies for durable adoption

In sum, hydrophilic coronary stents occupy a dynamic intersection of material science, pharmacology, and interventional technique, with adoption shaped by nuanced clinical needs, procurement realities, and evolving regulatory expectations. Advances in coating chemistry and polymer selection have materially influenced deliverability and healing considerations, while drug-eluting formulations continue to define device suitability across specific lesion types and patient profiles. As providers place greater emphasis on procedural efficiency and total procedural value, manufacturers must couple clinical differentiation with supply predictability and supportive services to secure durable adoption.

Regional and end-user heterogeneity means that no single commercial playbook will fit all contexts. Rather, success will stem from adaptive strategies that align evidence generation with the clinical segments and care settings most likely to derive tangible benefit. Moreover, external pressures such as tariff-driven supply-chain shifts underscore the importance of resilient sourcing strategies and flexible contracting frameworks. By centering decisions on demonstrable clinical outcomes, operational compatibility, and robust post-market surveillance, stakeholders can navigate the complexities of the current environment and position innovations to deliver measurable improvements in patient care and institutional performance.

Ultimately, the devices and strategies that combine clinical credibility, logistical reliability, and clear value propositions will be best positioned to influence procurement decisions and to support clinicians in delivering consistent, high-quality interventional care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hydrophilic Coronary Stents Market, by Stent Type

  • 8.1. Bare-Metal Stent
  • 8.2. Drug-Eluting Stent

9. Hydrophilic Coronary Stents Market, by Drug Type

  • 9.1. Everolimus
  • 9.2. Paclitaxel
  • 9.3. Sirolimus
  • 9.4. Zotarolimus

10. Hydrophilic Coronary Stents Market, by Polymer Material

  • 10.1. Biodegradable Polymer
  • 10.2. Durable Polymer

11. Hydrophilic Coronary Stents Market, by Stent Size

  • 11.1. 18 To 28 Mm
  • 11.2. Over 28 Mm
  • 11.3. Under 18 Mm

12. Hydrophilic Coronary Stents Market, by Clinical Application

  • 12.1. Acute Coronary Syndrome
    • 12.1.1. NSTEMI
    • 12.1.2. STEMI
    • 12.1.3. Unstable Angina
  • 12.2. Stable Angina

13. Hydrophilic Coronary Stents Market, by End User

  • 13.1. Ambulatory Surgical Center
  • 13.2. Hospital
    • 13.2.1. Private Hospital
    • 13.2.2. Public Hospital

14. Hydrophilic Coronary Stents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Hydrophilic Coronary Stents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Hydrophilic Coronary Stents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Hydrophilic Coronary Stents Market

18. China Hydrophilic Coronary Stents Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Apollo Endosurgery, Inc.
  • 19.7. B. Braun Melsungen AG
  • 19.8. Biotronik SE & Co. KG
  • 19.9. Boston Scientific Corporation
  • 19.10. Cook Medical LLC
  • 19.11. Edwards Lifesciences Corporation
  • 19.12. Endologix LLC
  • 19.13. Hansen Medical, Inc.
  • 19.14. Invuity, Inc.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Lepu Medical Technology (Beijing) Co., Ltd.
  • 19.17. Livar Stent Co., Ltd.
  • 19.18. Medtronic plc
  • 19.19. Meril Life Sciences Pvt. Ltd.
  • 19.20. MicroPort Scientific Corporation
  • 19.21. Philips Healthcare
  • 19.22. Relievant Medsystems, Inc.
  • 19.23. Shanghai MicroPort Medical (Group) Co., Ltd.
  • 19.24. Shanghai Shape Memory Alloy Co., Ltd.
  • 19.25. Siemens Healthineers AG
  • 19.26. Stryker Corporation
  • 19.27. Terumo Corporation
  • 19.28. Translumina GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYDROPHILIC CORONARY STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)